Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

EU’s Health Emergency Response Plans Must Address Existing Flaws

New HERA Authority Welcomed By Industry, But Current Weaknesses Highlighted

Executive Summary

The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.

You may also be interested in...



Europe's Generics Industry Takes Action To Maintain Medicines Access In Ukraine

Efforts are being made across the European off-patent community to bolster the supply chain and ensure access to medicines in Ukraine, says the generics and biosimilars industry association, Medicines for Europe. It has urged the EU to take a leading role in coordinating supplies through the new emergency response body, HERA.

Generics Industry Takes Action To Maintain Access In Ukraine

Efforts are being made across the European off-patent community to bolster the supply chain and ensure access to medicines in Ukraine, industry association Medicines for Europe tells Generics Bulletin. It has urged the EU to take a leading role in coordinating supplies through the HERA emergency response body.

Coronavirus Notebook: Nobel Laureates Press Germany To Back Vaccine IP Waiver

The EU vaunts its vaccine donations and starts building resilience against future health threats, and the UK MHRA says Moderna can be used as a booster dose. Aviptadil has received scientific advice from the MHRA for its potential use as a treatment for COVID-19 patients.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB151252

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel